Nkarta Q2 2026 net loss widens to $40.4 million, or $0.54 per share
Nkarta reported second-quarter 2026 results in a press release furnished as Exhibit 99.1. The clinical-stage biotechnology company posted a net loss of $40.4 million, or $0.54 per share, up from $23.0 million, or $0.31 per share, a year earlier, as total operating expenses rose to $43.1 million. The company said its $243.2 million in cash and investments is expected to fund operations into 2029.
Key points
- Net loss of $40.4 million, or $0.54 per share, for Q2 2026, versus $23.0 million, or $0.31 per share, for Q2 2025.
- Net loss included $8.0 million of impairment of right-of-use assets, leasehold improvements and other equipment.
- R&D expenses were $29.0 million and G&A expenses were $14.1 million in Q2 2026, versus $6.4 million G&A a year earlier.
- Cash, cash equivalents, restricted cash and investments were $243.2 million on June 30, 2026, expected to fund operations into 2029.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.